Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:27:20.810Z.
Consensus retrieved: 2026-10-06T14:24:08.235Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:27:20.810Z.
Quote observation: 2026-10-06T19:25:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bddae1a009f0b40e7fb659cb125a310776fd64778f9839bff19075a224db575c
Forward PE Ratio (N/A) = Dated Quote Price ($2.30) / Consensus Forward EPS ($-1.67)
FORWARD PE RATIO
N/A
Nkarta, Inc.
Market Cap
$164.55M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Nkarta, Inc. (NKTX) | $164.55M | N/A |
| OptimizeRx Corp. (OPRX)vs › | $165.13M | 9.81 |
| Cue Biopharma, Inc. (CUE)vs › | $168.48M | N/A |
| Quanterix Corporation (QTRX)vs › | $162.58M | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $162.23M | N/A |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.21M | N/A |
| MediWound Ltd. (MDWD)vs › | $169.24M | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $160.08M | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $171.41M | N/A |
| PepGen Inc. (PEPG)vs › | $159.44M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.30, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.67 | $-1.94 – $-1.30 | 4 | n/m |
| 2027-12-31 | $-1.52 | $-2.35 – $-0.66 | 4 | n/m |
| 2028-12-31 | $-1.33 | $-1.51 – $-1.20 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
